{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:26:13Z","timestamp":1794979573093,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"DOI":"10.1038\/s41537-025-00642-w","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T14:06:08Z","timestamp":1751983568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prevalence of cardiovascular risk factors and disease in patients with schizophrenia: baseline results from a prospective cohort study with long-term clinical follow-up"],"prefix":"10.1038","volume":"11","author":[{"given":"Christoffer","family":"Polcwiartek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svend Eggert","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Br\u00f8ndum","family":"Fr\u00f8kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 Ernst","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"642_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/eurheartj\/ehae054","volume":"45","author":"C Polcwiartek","year":"2024","unstructured":"Polcwiartek, C. et al. Severe mental illness: cardiovascular risk assessment and management. Eur. Heart J. 45, 987\u2013997 (2024).","journal-title":"Eur. Heart J."},{"key":"642_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eurpsy.2017.02.487","volume":"43","author":"N Jayatilleke","year":"2017","unstructured":"Jayatilleke, N. et al. Contributions of specific causes of death to lost life expectancy in severe mental illness. Eur. Psychiatry 43, 109\u2013115 (2017).","journal-title":"Eur. Psychiatry"},{"key":"642_CR3","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1001\/jamapsychiatry.2018.2742","volume":"75","author":"P Kugathasan","year":"2018","unstructured":"Kugathasan, P. et al. Association of secondary preventive cardiovascular treatment after myocardial infarction with mortality among patients with schizophrenia. JAMA Psychiatry 75, 1234\u20131240 (2018).","journal-title":"JAMA Psychiatry"},{"key":"642_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll, C. U. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16, 163\u2013180 (2017).","journal-title":"World Psychiatry"},{"key":"642_CR5","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1017\/S003329171300216X","volume":"44","author":"TM Laursen","year":"2014","unstructured":"Laursen, T. M., Mortensen, P. B., MacCabe, J. H., Cohen, D. & Gasse, C. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychol. Med 44, 1625\u20131637 (2014).","journal-title":"Psychol. Med"},{"key":"642_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jpsychires.2010.04.027","volume":"45","author":"TM Laursen","year":"2011","unstructured":"Laursen, T. M. & Nordentoft, M. Heart disease treatment and mortality in schizophrenia and bipolar disorder - changes in the Danish population between 1994 and 2006. J. Psychiatr. Res 45, 29\u201335 (2011).","journal-title":"J. Psychiatr. Res"},{"key":"642_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/archgenpsychiatry.2009.61","volume":"66","author":"TM Laursen","year":"2009","unstructured":"Laursen, T. M., Munk-Olsen, T., Agerbo, E., Gasse, C. & Mortensen, P. B. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch. Gen. Psychiatry 66, 713\u2013720 (2009).","journal-title":"Arch. Gen. Psychiatry"},{"key":"642_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","volume":"18","author":"RE Nielsen","year":"2021","unstructured":"Nielsen, R. E., Banner, J. & Jensen, S. E. Cardiovascular disease in patients with severe mental illness. Nat. Rev. Cardiol. 18, 136\u2013145 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"642_CR9","first-page":"354","volume":"46","author":"C Polcwiartek","year":"2020","unstructured":"Polcwiartek, C. et al. Electrocardiogram characteristics and their association with psychotropic drugs among patients with schizophrenia. Schizophr. Bull. 46, 354\u2013362 (2020).","journal-title":"Schizophr. Bull."},{"key":"642_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2215-0366(15)00115-7","volume":"2","author":"DC Henderson","year":"2015","unstructured":"Henderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M. & Copeland, P. M. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2, 452\u2013464 (2015).","journal-title":"Lancet Psychiatry"},{"key":"642_CR11","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1017\/S0033291718001812","volume":"49","author":"HC So","year":"2019","unstructured":"So, H. C., Chau, K. L., Ao, F. K., Mo, C. H. & Sham, P. C. Exploring shared genetic bases and causal relationships of schizophrenia and bipolar disorder with 28 cardiovascular and metabolic traits. Psychol. Med. 49, 1286\u20131298 (2019).","journal-title":"Psychol. Med."},{"key":"642_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008364","volume":"14","author":"C Polcwiartek","year":"2021","unstructured":"Polcwiartek, C. et al. Clinical heart failure among patients with and without severe mental illness and the association with long-term outcomes. Circ. Heart Fail 14, e008364 (2021).","journal-title":"Circ. Heart Fail"},{"key":"642_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019416","volume":"10","author":"C Polcwiartek","year":"2021","unstructured":"Polcwiartek, C. et al. Association between ECG abnormalities and fatal cardiovascular disease among patients with and without severe mental illness. J. Am. Heart Assoc. 10, e019416 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"642_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.schres.2019.12.019","volume":"216","author":"F Veru-Lesmes","year":"2020","unstructured":"Veru-Lesmes, F., Rho, A., Joober, R., Iyer, S. & Malla, A. Socioeconomic deprivation and blood lipids in first-episode psychosis patients with minimal antipsychotic exposure: Implications for cardiovascular risk. Schizophr. Res. 216, 111\u2013117 (2020).","journal-title":"Schizophr. Res."},{"key":"642_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.schres.2013.01.014","volume":"146","author":"VH Srihari","year":"2013","unstructured":"Srihari, V. H. et al. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. Schizophr. Res. 146, 64\u201368 (2013).","journal-title":"Schizophr. Res."},{"key":"642_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","volume":"6","author":"J Firth","year":"2019","unstructured":"Firth, J. et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 6, 675\u2013712 (2019).","journal-title":"Lancet Psychiatry"},{"key":"642_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","volume":"10","author":"M De Hert","year":"2011","unstructured":"De Hert, M. et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10, 52\u201377 (2011).","journal-title":"World Psychiatry"},{"key":"642_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","volume":"10","author":"M De Hert","year":"2011","unstructured":"De Hert, M. et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10, 138\u2013151 (2011).","journal-title":"World Psychiatry"},{"key":"642_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/wps.20384","volume":"16","author":"NH Liu","year":"2017","unstructured":"Liu, N. H. et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry 16, 30\u201340 (2017).","journal-title":"World Psychiatry"},{"key":"642_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2017.06.034","volume":"196","author":"B Kirkpatrick","year":"2018","unstructured":"Kirkpatrick, B. & Kennedy, B. K. Accelerated aging in schizophrenia and related disorders: future research. Schizophr. Res. 196, 4\u20138 (2018).","journal-title":"Schizophr. Res."},{"key":"642_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/08039488.2021.1939779","volume":"76","author":"ASK Aar\u00f8e","year":"2022","unstructured":"Aar\u00f8e, A. S. K. et al. Hepatic steatosis in patients with schizophrenia: a clinical cross-sectional study. Nord J. Psychiatry 76, 114\u2013119 (2022).","journal-title":"Nord J. Psychiatry"},{"key":"642_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03412-x","volume":"21","author":"T Trab","year":"2021","unstructured":"Trab, T. et al. Coronary artery calcium in patients with schizophrenia. BMC Psychiatry 21, 422 (2021).","journal-title":"BMC Psychiatry"},{"key":"642_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/08039488.2021.1902566","volume":"75","author":"M Omar","year":"2021","unstructured":"Omar, M. et al. Cardiovascular autonomic neuropathy in patients with schizophrenia. Nord J. Psychiatry 75, 547\u2013552 (2021).","journal-title":"Nord J. Psychiatry"},{"key":"642_CR24","volume":"26","author":"L Blok-Husum","year":"2023","unstructured":"Blok-Husum, L. et al. Cardiovascular autonomic reflex tests using a handheld device in the diagnosis of cardiovascular autonomic neuropathy in patients with schizophrenia. Am. Heart J. 26, 100252 (2023).","journal-title":"Am. Heart J."},{"key":"642_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12872-023-03143-9","volume":"23","author":"LR J\u00f8rgensen","year":"2023","unstructured":"J\u00f8rgensen, L. R. et al. Peripheral artery disease in patients with schizophrenia as compared to controls. BMC Cardiovasc Disord. 23, 126 (2023).","journal-title":"BMC Cardiovasc Disord."},{"key":"642_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/2468-5658.196979","volume":"1","author":"P Kugathasan","year":"2016","unstructured":"Kugathasan, P., Aagaard, J. & Jensen, S. E. Coronary artery disease as a cause of morbidity and mortality in patients suffering from schizophrenia: protocol for a prospective cohort study with long-term follow-up. Clin. Transl. Degener. Dis. 1, 141\u2013148 (2016).","journal-title":"Clin. Transl. Degener. Dis."},{"key":"642_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht, S. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951\u2013962 (2013).","journal-title":"Lancet"},{"key":"642_CR28","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735\u20132752 (2005).","journal-title":"Circulation"},{"key":"642_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","volume":"16","author":"R Ross","year":"2020","unstructured":"Ross, R. et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat. Rev. Endocrinol. 16, 177\u2013189 (2020).","journal-title":"Nat. Rev. Endocrinol."},{"key":"642_CR30","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration. (1976)."},{"key":"642_CR31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261\u2013276 (1987).","journal-title":"Schizophr. Bull."},{"key":"642_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1348\/014466502760387533","volume":"41","author":"M Startup","year":"2002","unstructured":"Startup, M., Jackson, M. C. & Bendix, S. The concurrent validity of the Global Assessment of Functioning (GAF). Br. J. Clin. Psychol. 41, 417\u2013422 (2002).","journal-title":"Br. J. Clin. Psychol."},{"key":"642_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamapsychiatry.2014.2133","volume":"72","author":"DP Osborn","year":"2015","unstructured":"Osborn, D. P. et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry 72, 143\u2013151 (2015).","journal-title":"JAMA Psychiatry"}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00642-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00642-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T14:06:12Z","timestamp":1751983572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-025-00642-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1038\/s41537-025-00642-w","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CP has received speaking fees from Lundbeck and research grant support from the Danish Cardiovascular Academy (grant number: CPD5Y-2021003-DCA), funded by the Novo Nordisk Foundation (grant number: NNF20SA0067242) and the Danish Heart Foundation. REN reported receiving research grants from H. Lundbeck and Otsuka Pharmaceuticals for clinical trials; receiving speaking fees from Bristol-Myers Squibb, Astra Zeneca, Janssen-Cilag, Lundbeck, Servier, Otsuka Pharmaceuticals, Teva A\/S, and Eli Lilly; has acted as advisor to Astra Zeneca, Eli Lilly, Lundbeck, Otsuka Pharmaceuticals, Takeda, and Medivir; and being an investigator for Janssen-Cilag, Lundbeck, Boehringer, Compass, and Sage. All other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}